Keerthana Pachalla’s Post

🌟 What an inspiring session this morning at #Dreamforce! 🌟 We had the privilege of hosting a groundbreaking discussion on "Revolutionizing Care with J&J’s Cell Therapy Platform," featuring insights from our very own Rajesh Singh, and Johnson & Johnson’s Advanced Therapies Product Group Leader Badri Sambamurthi. 🔬 Inside the Session: Rajesh and Badri delved into J&J’s innovative Cell & Gene Therapy platform—a true game-changer in personalized medicine. This platform leverages cutting-edge digital and AI capabilities to enhance patient experiences and significantly improve outcomes. Here’s what we heard: ➡️ Patient-Centric Approach: Johnson & Johnson’s approach emphasizes the importance of providing real-time updates to patients to ensure they are informed and supported throughout their treatment journey. ➡️ Continuous Learning: We help Johnson & Johnson implement innovative strategies to transform healthcare. That journey involves learning traditional biopharma methods, unlearning outdated practices, and relearning new ways to administer and distribute advanced therapies. ➡️ Targeted Therapies: Car-T therapies are revolutionizing care as they’re tailored for individual patients and offer personalized treatment options. This session was a testament to the power of collaboration and innovation in evolving healthcare. For Johnson & Johnson, it’s all about reimagining care and redefining living for patients. It’s exciting to see how digital advancements are paving the way for more effective and personalized treatments.

In three decades, cell therapies have transformed from science fiction to clinical reality. Can they now be advanced to become standard of care? #ISCT2024 confirmed the momentum carried by cell therapies, tackling unmet medical needs in cancer, genetic diseases, autoimmunity, and neurological disorders. Experiences gained with approved CAR-T therapies continue to to reveal that benefits clearly outweigh risks, as an #FDA speaker confirmed. In the meantime, promising results are hinting at potential new cures for currently intractable diseases. The cell therapy community’s ambition to tackle toughest challenges is higher than ever: At #ISCT2024, scientists, doctors, entrepreneurs, and investors presented their relentless efforts to advance process technologies, automation, data collection and AI-guided optimization, while striving to enable point-of-care or even bed-side manufacturing. But what struck us the most during these five days in Vancouver is a clear shift in mindset: Appreciating the hard-learned lessons that potent cells can turn useless when processed inadequately, most new therapy and technology developments are now targeted towards maximizing cell quality before cell quantity. We are extremely grateful for the inspiring and energizing discussions and are looking forward to seeing great progress in the field until the next edition of the ISCT, International Society for Cell & Gene Therapy conference! #ISCT2024 #Astraveus #Lakhesys #CGTmanufacturing #CellTherapy #Bioprocessing #Biotech

Latest DON Therapeutics news The future of healthcare is being transformed by groundbreaking advancements in gene therapy, cell therapy, and immunotherapy. These innovative treatments are pushing the boundaries of what's possible in medicine. By harnessing the power of genetic material, living cells, and the body's immune system, we can now target the root causes of diseases with unprecedented precision. Gene therapy offers the potential to repair or replace faulty genes, addressing genetic disorders at their core. Cell therapy utilizes living cells to regenerate and repair damaged tissues and organs, opening new frontiers in treating a wide range of conditions. Immunotherapy leverages the immune system to fight cancer and other diseases, creating highly targeted treatments with fewer side effects. Together, these therapies represent a new era in personalized medicine, offering hope and healing to millions worldwide. The convergence of these technologies is set to change the landscape of healthcare, making once-unthinkable treatments a reality. More about DON Therapeutics: https://lnkd.in/eKs-9g9e We are always looking for new healthcare opportunities. Submit your opportunity: https://lnkd.in/dJfhwVvv #biotech #seriesa #seriesb #healthcare #genetherapy #celltherapy #funding

This year’s ESACT was a great snapshot of a rapidly evolving cell and gene therapy (CGT) industry. Our experts Andrea Vervoort, Keara Sutherland, and Oliver Varette highlight 3 standout conference insights: ✔ The need for viral vectors is expected to continue to grow. This necessitates efficient and economical manufacturing methods to meet rising demand while also being mindful of environmental footprints. ✔ Industry leveraging AI/ML to model and optimize manufacturing processes, predict optimal outcomes and improve efficiency. Marinna Madrid, presented an AI/ML model for the automated production of stem cells for personalized regenerative cell therapies. There is also an emphasis on curating datasets and minimizing data silos within organizations. ✔ An excellent talk by Cath Green highlighted the benefits of providing robust biomanufacturing capabilities to academics. This enables important research to reach clinical trials, which is crucial for scenarios such as pandemics. Integrating industry and academia is pivotal for accelerating innovative therapies. Ultimately, CGT manufacturing is undeniably complex, and industry and academia collaboration is the cornerstone for the CGT sector to take transformative strides. #biomanufacturing #ESACT2024 #innovation

Clinical trials are not limited to evaluating the efficacy of medications. Researchers are exploring novel therapeutic interventions in clinical trials, including gene therapy, cell therapy, and medical devices. These advancements hold immense potential for treating a wide range of diseases and improving patient outcomes, highlighting the ever-evolving landscape of clinical research. However, challenges like slow rate of participation, less number of volunteers and more can hinder this growth. Read our blog series that sheds light on the challenges of clinical trial recruitment and proposals to address them here: https://lnkd.in/dE7-5jqp Follow Actu-Real for more insightful posts on healthcare, AI, machine learning, health economics, outcomes research, and real-world data. Looking for premium clinical trial support? Check out how Actu-Real can help - https://lnkd.in/dvePtiSE #ActuReal #Healthcare #ClinicalTrials #Trials

Transforming Healthcare with Innovation 🌟 Medical science is making strides with personalized treatments that are more targeted and precise than ever! Here's a quick look: Gene therapy is tackling once-untreatable diseases by fixing genetic issues at the source, sparking new hope. AI in diagnostics enhances speed and accuracy, improving patient care and saving time for medical staff. Precision oncology delivers more personalized cancer treatments, reducing invasiveness and increasing effectiveness. VR in surgery enhances training and enables risk-free rehearsal of complex operations, with global real-time collaboration. Nanomedicine improves drug delivery, reduces side effects, and detects diseases earlier. As we embrace these changes, patient outcomes and compassionate care remain paramount. Have these innovations touched your life? #HealthTech #NextGenMedicine #InnovationInHealthcare

With the global rise in #cancer cases, innovative #autologous #cell therapies are offering new hope to patients. The accessibility and therefore success of these promising treatments hinges on companies navigating key challenges in commercializing them. The personalized nature complicates standardization, but #automation can ensure accuracy in production, reduce overall COGS, and help scale production to meet demand. While full automation of these complex treatments remains a goal for the future, the industry can strive to integrate #manufacturingautomation to accelerate #speedtomarket and improve safety to continue advancing these promising treatments.

"The question is: how can we design future therapies to be more precise and patient-specific in this era of gene editing?" - Sumit Verma, Co-Founder & Partner Orchestra Life Sciences While #cancer cases continue to rise around the globe, groundbreaking #autologous #celltherapy treatments are providing new hope for patients and their families. While much of the industry's focus is on developing successful autologous cell therapies like CAR-T and Tumor Infiltrating Lymphocytes (#TIL), there are several considerations a company must note before commercialization including how automation and patient centricity can impact speed-to-market. In embracing automation, companies may experience improved patient outcomes through faster and more reliable production, enhanced scalability to meet ever growing global demand, and a reduction in errors with increased safety. Discover how OLS is helping automate processes to bring new therapies to life: https://lnkd.in/gJQFgAv9 #GeneTherapy #Radioligand #CART

Economist Impact - Join us at #EconCellGeneTherapySummit for 1.5 days in Brussels that will feature 60+ speakers in keynote plenaries and focus sessions on #cellandgenetherapy. These #treatments can be instrumental in the battle against cancer, #geneticdisorders and #rarediseases. With advances in technology and many innovative treatments on the horizon, cell and gene therapies can reshape healthcare, giving hope to patients who previously had no therapeutic options. But when will their potential be fully realised? Under the stewardship of The Economist’s editorial team, this event will convene industry leaders and healthcare stakeholders to debate the challenges of introducing advanced therapies into the mainstream. It will discuss changes in regulatory landscapes, delivery models, structuring clinical trials and gathering real-world evidence that can improve patient access while ensuring companies maintain a competitive edge. Register at: https://lnkd.in/dZWY7eic #AI #healthcare

Pharma Insights 2024! Stay ahead of the curve with these rare pharma facts: - Gene editing: CRISPR technology has been used to develop a treatment for sickle cell disease, with promising results in clinical trials. - AI-powered drug discovery: A new AI platform has identified potential treatments for Alzheimer's disease, showcasing the power of machine learning in pharma. - Personalized medicine: Advances in genetic testing have enabled tailored treatments for cancer patients, improving efficacy and reducing side effects. - Sustainable pharma: The industry is shifting towards eco-friendly manufacturing processes, reducing waste and environmental impact. - Global collaboration: International partnerships have accelerated vaccine development, demonstrating the power of collective innovation. Share your thoughts on these breakthroughs! #Pharma2024 #Innovation #GeneEditing #AI #PersonalizedMedicine #Sustainability